Table 1: General characteristics of the patients.
| IVR | IDI | p value | |
| Number of eyes | 19 | 22 | - |
| Age (years) | 58.5 ± 11.2 | 63.7 ± 11.0 | 0.1 |
| Gender (female/male) | 11/8 | 12/10 | 0.8 |
| Hypertension (%) | 13 (68%) | 12 (54%) | 0.2 |
| Diabetes (%) | 4 (21%) | 6 (27.2%) | 0.6 |
| Hyperlipidemia (%) | 2 (7.4%) | 2 (9.0%) | 0.8 |
| Macular ischemia on FA (non-ischemic/ischemic) |
4/15 | 8/14 | 0.2 |
| Type of RVO (BRVO/CRVO) | 13/6 | 12/10 | 0.3 |
| Lens status (phakic/pseudophakic) | 17/2 | 13/9 | 0.02* |
| Baseline BCVA (LogMAR) | 1.25 ± 0.58 | 1.15 ± 0.51 | 0.7 |
| Baseline CRT (micrometers) | 640 ± 191 | 623 ± 99 | 0.5 |
IVR: Intravitreal Ranibizumab; IDI: Intravitreal Dexamethasone Implant; P: p value; FA: Fluorescein Angiography; BRVO: Branch Retinal Vein Occlusion; CRVO: Central Retinal Vein Occlusion; BCVA: Best Corrected Visual Acuity; LogMAR: Logarithm of the Minimum Angle of Resolution; CRT: Central Retinal Thickness.
*p value less than 0.05 was considered statistically significant.